Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4807459 | 0.93 | MAPK14 (0.33) | NPC1RAB9ALMNAGAAHPGD | |
| Trifluoroacetic Acid SCHEMBL4809541 | 0.81 | MAPT (0.35) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4809310 | 0.80 | MEN1 (0.35) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4802588 | 0.79 | MEN1 (0.35) | HPGDSMN1; SMN2MAPK14L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL4809992 | 0.79 | ENPP2 (0.41) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4809932 | 0.79 | MAPK14 (0.35) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL4812018 | 0.77 | NPC1 (0.35) | NPC1RAB9ALMNAGAAHPGD | |
| SCHEMBL4812613 | 0.77 | MAPK14 (0.36) | NPC1RAB9ALMNAGAAHPGD | |
| Hydrochloric Acid SCHEMBL4806911 | 0.76 | MEN1 (0.36) | NPC1RAB9ALMNAGAAHPGD | |
| SCHEMBL4805867 | 0.76 | MAPT (0.38) | NPC1RAB9ALMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | NPC1 1831/4885RAB9A 2314/4885LMNA 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.